Table S3.

Adjusted mean FEV₁ responses (absolute change from baseline) at key time points

Mean (SE) AUC0–3, L	Study 1222.11			Study 1222.12
	Placebo (n=208)	Olodaterol 5 μg (n=206)	Olodaterol 10 μg (n=206)	Placebo (n=215)	Olodaterol 5 μg (n=207)	Olodaterol 10 μg (n=215)
Week 12 (coprimary end point)	−0.007 (0.014)	0.165 (0.014)****	0.169 (0.014)	0.008 (0.013)	0.159 (0.013)	0.152 (0.013)
Week 24	−0.018 (0.014)	0.156 (0.014)****	0.143 (0.014)****	−0.010 (0.013)	0.155 (0.013)****	0.126 (0.013)****
Week 48	−0.043 (0.014)	0.130 (0.014)****	0.126 (0.014)****	−0.030 (0.013)	0.132 (0.013)****	0.128 (0.013)****
Mean (SE) AUC0–3 difference from placebo, L
Week 12 (coprimary end point)		0.172 (0.019)****	0.176 (0.019)****		0.151 (0.017)****	0.143 (0.017)****
Week 24		0.174 (0.019)****	0.161 (0.019)****		0.165 (0.018)****	0.136 (0.018)****
Week 48		0.173 (0.019)****	0.169 (0.020)****		0.161 (0.018)****	0.158 (0.018)****
Mean (SE) trough, L	Study 1222.11			Study 1222.12
	Placebo (n=200)	Olodaterol 5 μg (n=199)	Olodaterol 10 μg (n=202)	Placebo (n=205)	Olodaterol 5 μg (n=205)	Olodaterol 10 μg (n=207)
Week 12 (coprimary end point)	−0.041 (0.014)	0.050 (0.014)****	0.060 (0.014)****	−0.003 (0.014)	0.044 (0.014)*	0.045 (0.014)**
Week 24	−0.050 (0.014)	0.036 (0.014)****	0.039 (0.014)****	−0.036 (0.014)	0.033 (0.014)***	0.022 (0.014)**
Week 48	−0.074 (0.014)	0.019 (0.014)****	0.017 (0.014)****	−0.057 (0.014)	0.011 (0.014)***	0.014 (0.014)***
Mean (SE) trough difference from placebo, L
Week 12 (coprimary end point)		0.091 (0.019)****	0.101 (0.019)****		0.047 (0.019)*	0.048 (0.019)**
Week 24		0.086 (0.019)****	0.089 (0.019)****		0.069 (0.019)*	0.058 (0.019)**
Week 48		0.092 (0.019)****	0.091 (0.019)****		0.068 (0.019)***	0.071 (0.019)***

Notes:

^*P<0.05 versus placebo;

^**P<0.01 versus placebo;

^***P<0.001 versus placebo;

^****P<0.0001 versus placebo.

Abbreviations: FEV₁, forced expiratory volume in 1 second; SE, standard error; AUC_0–3, area under the curve from 0–3 hours.